Unity Biotechnology snags additional $35 mln Series B
Unity Biotechnology, Inc, a developer of treatments that prevent, halt, or reverse numerous diseases of aging, has raised an additional $35 million in Series B financing, racking up a total of $151 million. Unity's investors included INVUS Opportunities, Three Lakes Partners, Cycad Group, COM Investments, Pivotal Alpha Limited. ARCH Venture Partners, Baillie Gifford, Fidelity Management and Research Company, Venrock. Bezos Expeditions, Vulcan Capital, Founders Fund, WuXi PharmaTech and Mayo Clinic Ventures.
17 August 2017•1 min read
